$PCSA: Catalyst Watch: Possible Licensing News by Tomorrow + Earnings on Oct 29
Processa Pharmaceuticals' 120-day licensing agreement window with Intact Therapeutics ends October 15, and a signed deal would bring $2.5M upfront plus up to $452.5M in potential milestones and royalties. The low-float micro-cap setup and upcoming earnings on October 29 create near-term catalysts that could drive a significant re-rating if the deal closes and validates the strategy of monetizing non-core assets.
At post $9.90live price unavailable
1d+3.5%
3d-22.7%
1w-24.2%
1m-26.3%
3m-68.3%
6m-72.0%
1y-83.7%
Listen up – PCSA’s 120-day deadline is next week (Oct 15th)
PCSA's 120-day deadline for finalizing a binding $454M licensing deal with Intact Therapeutics expires October 15th. Two of three likely outcomes (deal completion or extension with additional payment) are bullish, while a walk-away is least probable. The stock is consolidating on low volume in anticipation of this catalyst.
At post $9.48live price unavailable
1d—
3d+16.4%
1w-19.3%
1m-19.3%
3m-63.5%
6m-68.1%
1y-84.0%
$PCSA has a potential $454M+ licensing deal on the table
PCSA signed a binding term sheet with Intact Therapeutics for PCS12852 worth over $454M in potential milestone and royalty payments, creating a significant disconnect between the microcap's current valuation and upside if the deal closes and the drug progresses through trials and commercialization.
At post $9.83live price unavailable
1d-3.6%
3d-3.6%
1w-8.4%
1m-22.1%
3m-65.0%
6m-70.8%
1y-84.5%
$PCSA – Processa Pharmaceuticals – Why I’m Bullish AF.🚀
Stock exhibits a repeated intraday dip-and-rebound pattern with support holding on higher timeframes. The consistent absorption of dips and subsequent gap-ups suggest institutional buying, indicating further upside potential.
At post $11.98live price unavailable
1d-18.0%
3d-20.9%
1w-14.4%
1m-36.1%
3m-71.8%
6m-76.6%
1y-88.7%
“holding a small position with a $.30 average”
PSCA - A Biopharmaceutical - The Next Runner?
Processa Pharmaceuticals is a small-cap biopharmaceutical with pipeline catalysts in 2025-2026, including Phase 2/3 NGC-Gemcitabine trials, FDA discussions on PCS499, and investor conferences. The company has sufficient cash runway (7-9 months) to reach key milestones without near-term dilution threats, positioning it as a potential runner for early-stage biotech investors.
At post $9.00live price unavailable
1d+33.1%
3d+5.3%
1w+10.0%
1m-12.2%
3m-64.1%
6m-69.2%
1y-84.2%
$PCSA...low float biotech waking up ahead of a possible $450M+ licensing deal
Processa Pharmaceuticals is poised for a re-rating on a potential $452.5M licensing deal with Intact Therapeutics for its gastroparesis drug. The binding term sheet, combined with a tiny free float and recent unexplained volume spike, suggests early insider positioning ahead of an announcement that could unlock significant near-term cash and eliminate dilution concerns.
At post $9.00live price unavailable
1d+33.1%
3d+5.3%
1w+10.0%
1m-12.2%
3m-64.1%
6m-69.2%
1y-84.2%